Back to articles

Apixaban is an option for anticoagulation in patients on dialysis


Use of standard-dose apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) who are on dialysis was associated with a significantly lower risk of stroke/embolism, death, and major bleeding compared with warfarin, according to results of an observational study published in Circulation.


Siontis KC, et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation. 2018;[Epub ahead of print]. 

Eliquis [package insert]. Princeton, NJ, and New York, NY: Bristol-Myers Squibb, Pfizer; 2018. Accessed August 9, 2018.


Recent Articles